NETSCOUT Combines Leading Global Threat Intelligence With Machine Learning to Protect Enterprises From Rapidly Spreading Dynamic DDoS Attacks
11.7.2023 13:05:00 EEST | Business Wire | Press release
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT), a leading provider of performance management, cybersecurity, and DDoS attack protection solutions, today released its latest version of Arbor Edge Defense (AED) which includes new ML-based Adaptive DDoS Protection.
According to NETSCOUT's latest DDoS Threat Intelligence Report, there has been a significant increase in a new breed of dynamic DDoS attacks that use multiple vectors and techniques to launch botnet-based, direct-path, state exhaustion, and application-layer attacks designed to evade conventional static network and cloud-only-based DDoS defense.
Every enterprise is at grave risk today if they don’t deploy an effective DDoS solution on-premises to protect their network edge, internet-facing services, and critical stateful infrastructure such as firewalls and load balancers from these constantly evolving attacks. Attackers can send dynamic direct-path DDoS traffic at any time, and they can quickly change attack vectors during the attack making them nearly impossible to defend without the right technology. With AED’s Adaptive DDoS Protection, IT teams now have a scalable, always-on stateless packet processing solution that uses unmatched visibility into more than 50% of all internet traffic, global, real-time DDoS attack threat intelligence, decades of DDoS mitigation experience, and machine learning (ML) software intelligence to automatically detect, adapt to, and mitigate dynamic DDoS attacks.
“As cyber threats become more sophisticated and dynamic, IT teams need to out-smart bad actors with the ability to adapt and surgically block unwanted traffic at the network edge,” said Scott Iekel-Johnson, AVP, DDoS and Threat Intelligence at NETSCOUT. “With unmatched real-time visibility into global DDoS attack activity and decades of mitigation experience, no one knows more about DDoS attacks than NETSCOUT. With AED’s Adaptive DDoS Protection, enterprises can take advantage of our DDoS attack expertise and minimize unnecessary workloads that force expensive upgrades with an always-on product that can scale to protect every edge from a single pane of glass.”
Automated AED Protects Enterprises from Threats
Deployed at the Internet edge in front of any firewall, AED screens incoming and outgoing traffic using stateless packet processing, global DDoS threat intelligence, and ML to block inbound cyber threats, including DDoS attacks and other bulk malicious traffic. It protects and reduces the load on firewalls, load balancers, or VPN concentrators and stops the proliferation of malware within an organization. AED can also block outbound communications sent from compromised internal devices to sites run by bad actors to prevent data breaches and other malware activity. It contains the threat while giving the IT team time to investigate and remove it before it can cause further damage. In the event of a large volumetric DDoS attack, AED’s cloud signaling feature integrates with cloud DDoS protection providers, including NETSCOUT’s Arbor Cloud, to intelligently and automatically coordinate attack response between cloud-based volumetric protection and on-premise adaptive DDoS attack protection.
Visibility into 50% of All Internet Traffic
NETSCOUT ASERT, the company’s expert security research and DDoS attack mitigation team, works with over 500 Internet Service Providers (ISPs) to maintain a unique sensor network called ATLAS. With over 400 Tbps of international transit traffic received every second of every day from 93 countries, 600 industry verticals, and more than 31,000 autonomous systems, ATLAS provides ASERT with unmatched visibility into more than 50% of all internet traffic and real-time DDoS attack activity. ASERT analyzes the ATLAS data and distributes its findings to the Arbor Edge Defense (AED) solution via the ATLAS Intelligence Feed (AIF). AIF continually arms AED with highly curated intelligence that constantly updates the IP addresses of bots and reflectors/amplifiers actively participating in DDoS attacks around the globe. Created from real-world ASERT mitigation experience, AED’s Adaptive DDoS defense capabilities use ML-based algorithms to automatically recommend changes to attack countermeasures designed to stop dynamic DDoS attacks.
To learn more about how Adaptive DDoS Protection for AED automatically protects networks from dynamic DDoS attacks, visit our website.
About NETSCOUT
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) protects the connected world from cyberattacks and performance and availability disruptions through the company’s unique visibility platform and solutions powered by its pioneering deep packet inspection at scale technology. NETSCOUT serves the world’s largest enterprises, service providers, and public sector organizations. Learn more at www.netscout.com or follow @NETSCOUT on LinkedIn, Twitter, or Facebook.
©2023 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Visibility Without Borders, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, nGeniusONE, and Omnis are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230711112959/en/
Contact information
Maribel Lopez
Manager, Marketing & Corporate Communications
+1 781 362 4330
maribel.lopez@netscout.com
Chris Shattuck
Finn Partners for NETSCOUT
+1 404 502 6755
NETSCOUT-US@FinnPartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
